Strides subsidiary gets USFDA nod for Potassium Chloride tablets
Strides subsidiary gets USFDA nod for Potassium Chloride tablets

Strides subsidiary gets USFDA nod for Potassium Chloride tablets

Shohini Nath Article rating: 5.0

Strides Pharma Science’s step-down wholly-owned subsidiary, Vensun Pharmaceuticals, Inc., USA and its partner Pharmaceutics International, Inc. (Pii) have received approval for jointly developed Potassium Chloride Extended-Release Tablets.


Cyient hits 52-week low on Q4 business update
Cyient hits 52-week low on Q4 business update

Cyient hits 52-week low on Q4 business update

Amir Shaikh Article rating: 5.0

Leading software service provider Cyient announced the business update for Q4FY19 on Monday, reacting to which the stock of Cyient touched its 52-week low.

Ten stocks close to their 52-weeks high
Ten stocks close to their 52-weeks high

Ten stocks close to their 52-weeks high

Shital Jibhe Article rating: 5.0

The markets on April 02, 2019 opened flat. BSE Sensex is trading at 38,956.79, up by 84.92 points and the Nifty is trading at 11,688.60, up by 19.45 points. 

Steel Strips Wheels reports muted numbers for March
Steel Strips Wheels reports muted numbers for March

Steel Strips Wheels reports muted numbers for March

Amir Shaikh Article rating: 5.0

Steel Strips Wheels (SSWL) reported its performance for the month of March. The company managed to clock net turnover of Rs. 151.60 crore in March 2019, which represents nearly 10 per cent fall from March 2018.

Godrej Properties up 10 per cent on record performance in Q4
Godrej Properties up 10 per cent on record performance in Q4

Godrej Properties up 10 per cent on record performance in Q4

Amir Shaikh Article rating: 5.0

On the first day of the fiscal year 2019-20, the real estate developers Godrej Properties announced its Q4FY19 performance. The company in its exchange filing said that in the recently concluded quarter it recorded the highest ever booking and sold around 2,900 homes.

Lupin: Pithampur Unit III secures EIR from USFDA
Lupin: Pithampur Unit III secures EIR from USFDA

Lupin: Pithampur Unit III secures EIR from USFDA

Gayathri Udyawar Article rating: 5.0

The pharma company was issued an Establishment Inspection Report (EIR) for its Pithampur Unit-3 plant located near Indore, Madhya Pradesh, the company announced on Tuesday.

RSS
First26292630263126322634263626372638Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR